GlassScriptPhysician profile
Tal Ben Hazan
NPI 1497967376
$6,491.91
in general payments reported to CMS, 2019-2025
28 companies · $14.32 in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $573 · 2021: $1,900 · 2022: $1,582 · 2023: $1,087 · 2024: $660 · 2025: $14.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,812.46 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,201.54 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $583.61 | 2020-2025 | Stelara, Simponi, Simponi Aria |
| Boston Scientific Corporation | $358.76 | 2019-2023 | Cre Pro |
| Celgene Corporation | $311.13 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $186.98 | 2019-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $162.47 | 2020-2024 | Entyvio |
| Ironwood Pharmaceuticals, INC | $119.44 | 2020-2023 | Linzess |
| Genzyme Corporation | $116.57 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $114.74 | 2019-2024 | |
| Pentax of America, INC. | $73.29 | 2022 | |
| Tersera Therapeutics LLC | $51.89 | 2021 | |
| Qol Medical, LLC | $44.92 | 2022-2023 | Sucraid |
| Amgen INC. | $41.57 | 2020-2021 | |
| Mylan Institutional INC. | $37.57 | 2023 | Hulio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $35.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.60 | 2022 | |
| Merck Sharp & Dohme LLC | $29.78 | 2021-2022 | |
| Redhill Biopharma INC. | $27.32 | 2021 | |
| Lilly USA, LLC | $24.17 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $23.41 | 2023 | Dupixent |
| Shionogi INC | $21.61 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $16.37 | 2024 | Bylvay |
| Braintree Laboratories, INC. | $15.30 | 2021 | |
| Nestle Healthcare Nutrition INC. | $13.39 | 2021 | |
| Pfizer INC. | $13.15 | 2019 | |
| Gilead Sciences, INC. | $11.31 | 2020 | |
| Dova Pharmaceuticals | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tal Hazan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.